Qiagen N.V.

Ladies and gentlemen, thank you for standing by. I am Shelly, your global meet operator. Welcome and thank you for joining QIAGEN's Q2 2026 earnings conference call webcast. At this time, all participants are in a listen-only mode. Please be advised that the call is being recorded at QIAGEN's request and will be made available on their internet website. The prepared remarks will be followed by a question and answer session. If you would like to ask a question, you may press star followed by one on your touchtone telephone keypad. Please press the star key followed by zero for operator assistance. At this time, I would like to introduce your host, Daniel Wendorff, Vice President, Head of Investor Relations at QIAGEN. Please go ahead.

Thank you, operator. and welcome to our call for the second quarter of 2026. We appreciate your time and interest in QIAGEN. Joining the call today are Thierry Bernard, our chief executive officer, and Roland Sackers, our chief financial officer. Also joining us is Dr. Dominika Matarana from our Investor Relations team. As always, today's call is being webcast live and will be archived in the Investor Relations section of our website at www.qiagen.com. where you can find the press release and presentation accompanying this call. Please also note that this call will include forward-looking statements. Actual results may differ materially from those projected due to a number of factors outlined in our most recent Form 20F and other filings with the U.S. Securities and Exchange Commission. We will also refer to certain financial measures not prepared in accordance with U.S. generally accepted accounting principles or GAP. that provide additional insights into our performance. Reconciliations to the most directly comparable gap figures are in the release and presentation. All references to earnings per share refer to adjusted diluted EPS. With that, let me hand over the call to you, Thierry.

Thank you, Daniel. Hello and good morning, good afternoon or good evening, depending on where you are in the world. And thank you for joining us. Let me start by thanking again our teams across QIAGEN for their continued dedication and disciplined execution. Their focus enabled us to deliver results above our outlook while continuing to invest in our portfolio and focus on profitable growth. Let me now walk you through our key messages for today. We exceeded our outlook for both sales and adjusted EPS. Net sales were $535 million and unchanged on both a reported basis and at CER. This was ahead of our outlook for an approximately 2% decline CER. Adjusted diluted EPS was 62 cents on both a reported basis and at CER again, above our outlook of at least 60 cents at CER. Those results demonstrate the resilience of our business and provide further confidence in our outlook for the year. Second key message. Our growth pillars delivered 5% growth at CER, probably above market growth. Sample technologies led the quarter, reflecting continued demand for our sample preparation solutions. Kayaquiti delivered another solid quarter, driven by healthy consumables demand. QDI, our bioinformatics business, also performed well led by our clinical application. Quantiform return to growth as solid demand across many testing groups more than offset the significant decline in U.S. immigration testing demand. This U.S. immigration testing demand decrease is what we highlighted at the end of our Q1, 2026. Chiostat diagnostic. was impacted by a challenging prior year comparison in respiratory testing, partially offset by continued strong growth in our gastrointestinal and meningitis-encephalitis panels, with the gastrointestinal panel performing particularly well. Third key message, we maintain a very high level of profitability. This reflects our ability to improve efficiency. while continuing to invest for future growth. Fourth, we continue to generate strong cash flow providing the financial flexibility to invest in the business while returning capital to shareholders. This financial strength enabled us to increase our annual dividend by 40% in 2026. And this brings me to my final key message for today. Our outlook for 2026. We are reaffirming our full year outlook and remain confident in stronger growth during the second half of the year. The continued performance of our growth pillars and the progress we are making across our portfolio reinforce our confidence in delivering the outlook we have set for the year. With that, I'll turn over to Roland for more details on the financials.